Table 4 |
|||
|
Risk (%) of adverse events (of moderate or greater severity) associated with study treatment within the first 42 days of treatmentΔ |
|||
| Adverse events |
AQ+SP (n = 396) |
AS+AQ (n = 362) |
AL (n = 362) |
|
|
|||
| Coryza |
10.0% |
12.2% |
13.1% |
| Cough |
14.7% |
22.8% |
20.9% |
| Anorexia* |
10.3% |
9.7% |
5.5% |
| Weakness† |
9.7% |
6.5% |
3.1% |
| Abdominal pain |
6.0% |
3.3% |
3.4% |
| Vomiting |
3.8% |
1.7% |
1.9% |
| Subjective fever |
24.9% |
22.8% |
24.2% |
| Headache |
1.5% |
2.8% |
3.4% |
| Rash |
6.0% |
5.5% |
4.7% |
| Generalized pruritus |
7.4% |
8.2% |
6.5% |
| Diarrhoea‡ |
0.7% |
1.1% |
3.2% |
| Elevated temperatureγ |
4.8% |
4.5% |
9.2% |
| Nausea |
1.0% |
0.3% |
0.3% |
| Hepatosplenomegaly |
0.3% |
0.3% |
0.3% |
|
|
|||
|
ΔRisk estimated by Kaplan-Meier product limit formula * Anorexia: AQ+SP vs. AL, p = 0.005 † Weakness: AQ+SP vs. AL, p < 0.001 ‡ Diarrhoea: AL vs. AQ+SP, p = 0.021 γ Elevated Temperature: AL vs. AQ+SP, p = 0.029; AL vs. AS+AQ, p = 0.008 |
|||
|
Maiteki-Sebuguzi et al. Malaria Journal 2008 7:106 doi:10.1186/1475-2875-7-106 |
|||
